Pharmigene, Inc. (TPEX:7595)

Market Cap	529.88M -30.9%
Revenue (ttm)	149.25M +17.4%
Net Income	-75.51M
EPS	-1.50
Shares Out	50.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	28,944
Open	10.50
Previous Close	10.50
Day's Range	10.50 - 10.50
52-Week Range	9.50 - 15.00
Beta	0.07
RSI	54.13
Earnings Date	Mar 13, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 42
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7595

Financial Performance

In 2024, Pharmigene's revenue was 116.53 million, a decrease of -12.19% compared to the previous year's 132.71 million. Losses were -82.86 million, 14.1% more than in 2023.